Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HSTO Stock Summary
In the News
Top Sectors to Explore for Penny Stocks to Buy
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Psychology: Developing a Winning Mindset
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Histogen (HSTO) Stock Up 37% Today?
Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.
Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know
Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Buying Biotech Penny Stocks? 3 Things to Look For
Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen's Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.
HSTO Financial details
HSTO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 11.06 | 19.14 | 4.57 | 0.48 | 1.17 | |
Net income per share | -5.93 | -8.29 | -57.16 | -7.51 | -3.26 | |
Operating cash flow per share | -11.48 | -2.19 | -26.73 | -7.58 | -3.02 | |
Free cash flow per share | -11.5 | -2.44 | -26.84 | -7.7 | -3.08 | |
Cash per share | 13.4 | 3.5 | 15 | 9.74 | 3.77 | |
Book value per share | 9.02 | -62.76 | 17.43 | 11.05 | 4.49 | |
Tangible book value per share | 9.02 | -64.28 | 15.33 | 10.52 | 4.17 | |
Share holders equity per share | 9.02 | -62.76 | 17.43 | 11.05 | 4.49 | |
Interest debt per share | 0.21 | 0.25 | 11.61 | 2.48 | 1.44 | |
Market cap | 1.05B | 47.26M | 6.85M | 12.66M | 2.67M | |
Enterprise value | 1.04B | 45.34M | 5.39M | -1.28M | -4.82M | |
P/E ratio | -58.35 | -9.65 | -0.27 | -0.88 | -0.25 | |
Price to sales ratio | 31.29 | 4.18 | 3.33 | 13.78 | 0.71 | |
POCF ratio | -30.15 | -36.6 | -0.57 | -0.87 | -0.28 | |
PFCF ratio | -30.09 | -32.75 | -0.57 | -0.86 | -0.27 | |
P/B Ratio | 38.35 | -1.27 | 0.87 | 0.6 | 0.19 | |
PTB ratio | 38.35 | -1.27 | 0.87 | 0.6 | 0.19 | |
EV to sales | 30.94 | 4.01 | 2.62 | -1.39 | -1.28 | |
Enterprise value over EBITDA | -60.34 | 43.18 | -1.18 | 0.08 | 0.45 | |
EV to operating cash flow | -29.81 | -35.12 | -0.45 | 0.09 | 0.5 | |
EV to free cash flow | -29.76 | -31.42 | -0.45 | 0.09 | 0.49 | |
Earnings yield | -0.02 | -0.1 | -3.76 | -1.14 | -3.93 | |
Free cash flow yield | -0.03 | -0.03 | -1.77 | -1.17 | -3.71 | |
Debt to equity | 0 | 0 | 0.67 | 0.22 | 0.32 | |
Debt to assets | 0 | 0.05 | 0.35 | 0.17 | 0.24 | |
Net debt to EBITDA | 0.67 | -1.83 | 0.32 | 0.9 | 0.7 | |
Current ratio | 2.56 | 1.78 | 3.02 | 9.27 | 10.9 | |
Interest coverage | -26.26 | 0 | 183.03 | -1.55K | -10.64K | |
Income quality | 1.94 | 0.43 | 0.64 | 0.97 | 0.91 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.31 | 0.55 | 3.2 | 8.48 | 2.49 | |
Research and developement to revenue | 1.23 | 0.36 | 3.02 | 9.22 | 1.33 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.12 | 0 | 0.02 | 0.02 | |
Capex to revenue | 0 | -0.01 | -0.02 | -0.26 | -0.06 | |
Capex to depreciation | -0.73 | -1.05 | -0.5 | -2.48 | -1.54 | |
Stock based compensation to revenue | 0.11 | 0.04 | 0.3 | 0.77 | 0.13 | |
Graham number | 34.7 | 108.2 | 149.73 | 43.21 | 18.15 | |
ROIC | -0.7 | -0.04 | -0.89 | -0.48 | -0.44 | |
Return on tangible assets | -0.37 | -1.66 | -1.72 | -0.53 | -0.55 | |
Graham Net | 7.26 | -65.53 | -2.39 | 6.58 | 2.08 | |
Working capital | 28.91M | 1.08M | 5.62M | 19.28M | 12.22M | |
Tangible asset value | 27.4M | -37.97M | 6.91M | 20.19M | 13.38M | |
Net current asset value | 26.02M | -38.45M | 300K | 14.55M | 7.76M | |
Invested capital | 0 | 0 | 0.67 | 0.22 | 0.32 | |
Average receivables | 3.52M | 1.89M | 127K | 154.5K | 132K | |
Average payables | 0 | 404K | 673.5K | 966K | 887.5K | |
Average inventory | 0 | 53K | 203K | 1.01M | 1.06M | |
Days sales outstanding | 39.96 | 3.55 | 25.53 | 65.53 | 9.59 | |
Days payables outstanding | 0 | 133.15 | 203.24 | 2.31K | 0 | |
Days of inventory on hand | 0 | 17.47 | 113.12 | 2.87K | 0 | |
Receivables turnover | 9.13 | 102.76 | 14.3 | 5.57 | 38.07 | |
Payables turnover | 0 | 2.74 | 1.8 | 0.16 | 0 | |
Inventory turnover | 0 | 20.9 | 3.23 | 0.13 | 0 | |
ROE | -0.66 | 0.13 | -3.28 | -0.68 | -0.73 | |
Capex per share | -0.02 | -0.26 | -0.11 | -0.13 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.01 | -0.93 | -0.81 | -0.49 | -0.9 | |
Operating cash flow per share | -0.69 | -0.76 | -0.6 | -0.56 | -0.63 | |
Free cash flow per share | -0.69 | -0.76 | -0.6 | -0.56 | -0.63 | |
Cash per share | 4.09 | 3.77 | 2.26 | 1.7 | 1.07 | |
Book value per share | 4.86 | 4.49 | 2.66 | 2.18 | 1.27 | |
Tangible book value per share | 4.57 | 4.17 | 2.42 | 1.93 | 1.03 | |
Share holders equity per share | 4.86 | 4.49 | 2.66 | 2.18 | 1.27 | |
Interest debt per share | 1.32 | 1.44 | 1.07 | 1.06 | 0 | |
Market cap | 4.8M | 2.67M | 5.17M | 3.03M | 2.2M | |
Enterprise value | -5.07M | -4.81M | 85.83K | 287.95K | -2.37M | |
P/E ratio | -0.33 | -0.22 | -0.37 | -0.36 | -0.14 | |
Price to sales ratio | 959.75 | 666.31 | 1.03K | 606.59 | 439.65 | |
POCF ratio | -1.96 | -1.09 | -2.03 | -1.27 | -0.82 | |
PFCF ratio | -1.95 | -1.09 | -2.03 | -1.27 | -0.82 | |
P/B Ratio | 0.28 | 0.19 | 0.46 | 0.33 | 0.4 | |
PTB ratio | 0.28 | 0.19 | 0.46 | 0.33 | 0.4 | |
EV to sales | -1.01K | -1.2K | 17.17 | 57.59 | -474.95 | |
Enterprise value over EBITDA | 1.42 | 1.64 | -0.02 | -0.14 | 0.67 | |
EV to operating cash flow | 2.07 | 1.97 | -0.03 | -0.12 | 0.88 | |
EV to free cash flow | 2.06 | 1.97 | -0.03 | -0.12 | 0.88 | |
Earnings yield | -0.75 | -1.12 | -0.67 | -0.69 | -1.75 | |
Free cash flow yield | -0.51 | -0.92 | -0.49 | -0.79 | -1.22 | |
Debt to equity | 0.27 | 0.32 | 0.4 | 0.49 | 0 | |
Debt to assets | 0.21 | 0.24 | 0.29 | 0.33 | 0 | |
Net debt to EBITDA | 2.77 | 2.55 | 1.48 | 1.34 | 1.3 | |
Current ratio | 11.69 | 10.9 | 7.92 | 8.54 | 4.05 | |
Interest coverage | -3.6K | 2.97K | 3.47K | -2.09K | 0 | |
Income quality | 0.68 | 0.82 | 0.73 | 1.15 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 539.2 | 470.75 | 497.2 | 311.4 | 574 | |
Research and developement to revenue | 181.4 | 272.25 | 198.6 | 107.2 | 132 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -1.8 | -0.25 | 0 | 0 | 0 | |
Capex to depreciation | -0.24 | -0.03 | 0 | 0 | 0 | |
Stock based compensation to revenue | 26.6 | 22.25 | 83.8 | 6.4 | -1.4 | |
Graham number | 10.52 | 9.69 | 6.97 | 4.9 | 5.08 | |
ROIC | -0.13 | -0.13 | -0.17 | -0.11 | -0.64 | |
Return on tangible assets | -0.16 | -0.16 | -0.22 | -0.15 | -0.66 | |
Graham Net | 2.52 | 2.09 | 0.97 | 0.46 | 0.74 | |
Working capital | 14.94M | 12.22M | 9.27M | 7.31M | 4.11M | |
Tangible asset value | 16.25M | 13.38M | 10.32M | 8.27M | 4.4M | |
Net current asset value | 10.41M | 7.76M | 4.88M | 3M | 4.04M | |
Invested capital | 0.27 | 0.32 | 0.4 | 0.49 | 0 | |
Average receivables | 199.5K | 86.5K | 61K | 11.5K | 0 | |
Average payables | 547.5K | 471.5K | 411.5K | 417.5K | 390K | |
Average inventory | 617.5K | 535.5K | 432.5K | 192K | 0 | |
Days sales outstanding | 1.33K | 2.23K | 414 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.07 | 0.04 | 0.22 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.21 | -0.21 | -0.31 | -0.23 | -0.71 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
HSTO Frequently Asked Questions
What is Histogen Inc. stock symbol ?
Histogen Inc. is a US stock , located in San diego of Ca and trading under the symbol HSTO
What is Histogen Inc. stock quote today ?
Histogen Inc. stock price is $0.3601 today.
Is Histogen Inc. stock public?
Yes, Histogen Inc. is a publicly traded company.